MetaCap

Sagimet Biosciences Inc. Series A Company Profile

NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.08-0.54 (-5.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Sagimet Biosciences Series A at a glance

Sagimet Biosciences Inc. Series A (NASDAQ: SGMT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Mateo, CA. Sagimet Biosciences Series A is led by Mr. David A. Happel and employs about 16 people. The company's shares have traded publicly since 2023.

At a market capitalization of $648.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001400118, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Sagimet Biosciences Series A do?

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Business description based on the company's public filings.

Company information

Legal name
Sagimet Biosciences Inc. Series A
Ticker
NASDAQ: SGMT
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. David A. Happel
Employees
16
Headquarters
155 Bovet Road, San Mateo, CA, United States
Phone
650 561 8600
IPO year
2023
Market cap
$648.02M
SEC CIK
0001400118
Latest annual report
10-K · Mar 11, 2026

Companies similar to Sagimet Biosciences Series A

SGMT peer companies
CompanyPrice% ChgMarket capCompare
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs SGMT
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs SGMT
APMDApnimed Inc.16.09-6.70%$669.84Mvs SGMT
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs SGMT
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs SGMT
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs SGMT
LXRXLexicon Pharmaceuticals Inc.1.53-8.38%$681.21Mvs SGMT
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs SGMT

Related